NR4A1 and breast cancer: In the Study of Anastrozole with the Bisphosphonate Risedronate (SABRE) trial, oral risedronate 35 mg once weekly was assessed in post‐menopausal women with hormone receptor‐positive early breast cancer undergoing adjuvant anastrozole therapy, stratified by fracture risk.